Can we forecast induction failure in acute myeloid leukemia?
- 28 February 2018
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (3), 375-377
- https://doi.org/10.3324/haematol.2018.187575
Abstract
Standard induction therapy for fit patients with acute myeloid leukemia (AML) consists of a combination therapy with anthracycline and cytarabine. This classical regimen, typically called “7+3”, has not changed for several decades.[1][1] While many patients achieve a complete remission (CR) withThis publication has 16 references indexed in Scilit:
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AMLBlood, 2017
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2016
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 2015
- How I treat refractory and early relapsed acute myeloid leukemiaBlood, 2015
- Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemiaLeukemia, 2015
- Treatment of acute myeloid leukemia: are we making progress?Hematology, 2012
- Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesThe Lancet, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.1998